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Abstract We have derived 30 human embryonic stem cell
lines from supernumerary blastocysts in our laboratory.
During the derivation process, we have studied new and
safe method to establish good quality lines. All our human
embryonic stem cell lines have been derived using human
foreskin fibroblasts as feeder cells. The 26 more recent lines
were derived in a medium containing serum replacement
instead of fetal calf serum. Mechanical isolation of the inner
cell mass using flexible metal needles was used in deriving
the 10 latest lines. The lines are karyotypically normal, but
culture adaptation in two lines has been observed. Our
human embryonic stem cell lines are banked, and they are
available for researchers.
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Introduction
Human embryonic stem cells (hESC), first reported in 1984
(Fishel et al. 1984), and as permanent lines 10 yr ago
(Thomson et al. 1998; Reubinoff et al. 2000), are for the
time being in the center of biological and medical research.
They have great potential for use in clinical applications in
regenerative medicine due to their ability to form all the
tissue types in the body. Before clinical applications, many
quality and safety requirements have to be met (Crook et al.
2007). In our derivations, we have developed culture
systems in which we could at first avoid mouse fibroblasts
as feeder cells and then fetal calf serum (FCS) and
immunosurgery, which all involve animal proteins which
are immunogenic (Martin et al. 2005) and bear a risk of
microbial contamination (Unger et al. 2008). We have
derived in our laboratory 30 hESC lines. They were derived
from blastocyst stage supernumerary embryos donated for
this purpose by couples treated in the in vitro fertilization
(IVF) unit of our hospital.
We have successfully derived and cultured them on
postnatal human foreskin fibroblasts (hff), completely
avoiding the use of animal cells as feeders (Hovatta et al.
2003). Our second step toward clinical grade hESC lines
was to use a serum replacement (SR) as a constituent of the
medium, first in culture of the existing lines, instead of FCS
(Koivisto et al. 2004) and then also in the derivation
medium of the following lines (Inzunza et al. 2005).
To further minimize the use of animal-derived substan-
ces, we developed a method to mechanically isolate the
inner cell mass (ICM) to replace the use of immunosurgery
(Strom et al. 2007) that involves animal components and
enzymes. For the time being, we have derived 10 hESC
lines using mechanical isolation of the ICM.
Here, we describe the derivation procedures of our 30
hESC lines.
Materials and Methods
Legal and ethics framework in Sweden and embryos used.
The Swedish law allows derivation and culture of hESC
lines from human supernumerary IVF embryos after both
partners’ informed consent. No reimbursement is allowed.
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establishing embryos for research purposes has also been
allowed in particular situations which cannot be solved by
any other method, under the approval of a regional ethics
board.
We have ethics approval from the Ethics Board of
Karolinska Institutet and the Regional Ethics Board in
Stockholm for derivation and culture, expansion, banking,
and differentiation of hESC lines from supernumerary
embryos. We also have an approval for studying the
possibility for obtaining hESC lines using somatic cell
nuclear transfer (SCNT) to in vitro matured oocytes which
could not be injected by sperm in treatment of male
infertility. We have only obtained a few oocytes for this
study, and we have not managed to derive any hESC lines
using SCNT. We are now focusing more to induced
pluripotent cells in achieving patient-specific cell lines.
All our lines have been derived from blastocyst stage
embryos which were donated by couples undergoing IVF
treatment in our hospital. Only embryos which could not be
used in the couples’ infertility treatment were used for hESC
derivation. During the treatment process, the best embryo is
transferred to the woman, occasionally two if the embryo
quality is scored as poor or the couple has undergone more
than two unsuccessful treatment cycles earlier. The rest of the
embryos which meet the score of at least 2 out of 3.5
(Fridstrom et al. 1999) are cryopreserved. The low scoring
embryos were discarded or could be donated for research
until 2008, but now, all are cultured to blastocyst stage. If
they reach this stage, they will be vitrified for the couple’s
possible later infertility treatment. The maximum cryopres-
ervation time for embryos in Sweden is 5 yr. If they are not
used for infertility treatment before the end of this period,
they are discarded or donated to research. During the first
visit to the IVF unit, the couple is given both written and oral
information regarding the research projects in the unit,
including stem cell line derivation (Bjuresten and Hovatta
2003). The couples sign an informed consent form approved
by the ethics committee. They do not get financial
reimbursement for the donation. A specially educated
midwife gave the counseling.
Iftherewere,afterthefirstembryotransfer,embryoswhich
had too low score for cryopreservation at cleavage stage, or if
the couple did not want to use the cryopreserved embryos for
their treatment anymore, they could be donated for stem cell
derivation. If the embryo was donated at cleavage stage to
hESC derivation, the IVF laboratory cultured it to blastocyst
stage before transfer to the stem cell laboratory.
In 2002–2009, we have used 236 blastocysts in stem cell
derivation.
Embryo culture. The embryos were cultured in IVF medium
(Vitrolife, Göteborg, Sweden) individually in 20-μld r o p l e t s
under oil for the first 2 d and then transferred to blastocyst
medium (Vitrolife). From 2006 up until today, the early
embryos are cultured in ISM1 and moved to ISM2 (both
from Medicult, Jyllinge, Denmark) on Day 3. Oocyte and
embryo culture was performed in 20-μl drops of culture
medium under paraffin oil (Ovoil, Vitrolife) in an atmo-
sphere of 6% CO2 in air at 37°C.
Isolation of the inner cell mass by immunosurgery. The first
20 hESC lines HS181–HS402 (Table 1) were derived by
immunosurgery described earlier by Solter and Knowles
(1975). The zona pellucida was first removed using 0.5%
Pronase (Sigma-Aldrich Co., St Louis, MO). The trophec-
toderm cells are then removed by using rabbit antihuman
whole serum and guinea pig complement serum (both from
Sigma-Aldrich). The isolated ICM was then plated on
human foreskin fibroblast feeder cells.
Mechanical isolation of the inner cell mass. The blastocyst
is put in a small drop of stem cell culture medium, and the
zonapellucidaisopenedupwithspeciallymadeflexiblemetal
needles (0.125 mm in diameter; Strom et al. 2007). These
needles have now become commercially available (Hunter
Scientific, Essex, UK). The embryo was fixed at the edge of
the drop and opened up with the needles, and the ICM was
dissected out. The procedure took 20–40 s under a
stereomicroscope (Nikon 1500). The ICM was allowed to
grow on the human skin feeder cells for 12–15 d before the
first transfer of the growing cells to a new feeder plate.
Feeder cells. Human foreskin fibroblasts as feeder cells
(CRL-2429; ATCC, Mananas, VA) have been used in all
our derivations. Before being used as substrate cells, they
had been irradiated with 40 Gy. The medium used in
culture of these feeder cells was Iscovs medium (Gibco
Invitrogen Corp., Paisley, UK) supplemented with 10%
FCS (FCS; SDS, Sweden).
Human embryonic stem cell derivation and maintenance
cultures. The culture medium used for derivation of the
first four hESC lines (HS181, HS207, HS235, HS237) was
Knockout D-MEM 13, supplemented with 2 nmol/l
L-glutamine (both from Gibco), 20% fetal bovine serum
(FBS; R&D, Sweden), 0.1 mmol/l b-mercaptoethanol
(Gibco), 1% nonessential amino acids (Gibco), and recom-
binant human LIF, 1 μl/ml (Chemicon, Temecula, CA;
Hovatta et al. 2003). The later derivations of hESC lines
HS293–HS539 have been derived and cultured in Knock-
out Dulbecco´s modified Eagle´s medium supplemented
with 20% Knockout serum replacement, 2 mM Glutamax,
0.5% penicillin–streptomycin, 1% nonessential amino
acids, 0.5 mM 2-mercaptoethanol (all from Gibco), and
8 ng/ml basic fibroblast growth factor (bFGF; R&D
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described (Inzunza et al. 2005; Strom et al. 2007). We also
tested derivation in X-vivo 10 (Cambrex Corporation, East
Rutherford, NJ), but no lines were achieved from the 20
blastocysts used in this series.
During derivation and early culture, the hESCs were
mechanically passaged in 5–7-d intervals by the use of a
surgical scalpel.The colonieswereliftedfromthe feederlayer
in smaller pieces and then transferred onto fresh feeder cells.
At later passages, also enzymatic passaging using
dispase (5 mg/mL, StemCell Tech Inc., Vancover, BC,
Canada), collagenase type IV, and more recently, human
recombinant trypsin, TrypLE Select/Express (all from
Gibco) has been used but are not used as routine. Culture
form single cell suspension has been feasible using a Rho-
kinase inhibitor Y-27632, (Merck Chemicals Ltd., Notting-
ham, UK; Martin-Ibanez et al. 2008).
All hESC lines that we have derived have also been
cultured and maintained on a similar feeder layer of human
foreskin fibroblasts and the same SR-supplemented culture
medium as has been described for derivation procedures.
Feeder-free cultures have been used for many experi-
ments, particularly those aimed at gene expression studies.
Several culture systems have been tested, but our regular
feeder-free culture matrix has been Matrigel (BD Bioscien-
ces, Bedford, MA) together with mTeSR1 Medium (Stem-
Cell Tech. Inc.), which supports the growth of all the lines.
We have recently developed a new human recombinant
laminin 511 matrix which supports the long-term non-
differentiated growth of hESC together with a defined
xeno-free medium (Rodin et al. 2010).
Vitrification. When a new hESC line has been derived, it is
important to freeze cells at an early stage as possible. By
using the open-pulled straw vitrification method described
for the first time by Reubinoff et al. (2001), it is possible to
freeze small amounts of cells. In short, ministraws were
heat-softened over a hot plate and manually pulled until
reaching optimal diameter. After cooling to room temper-
ature, the straws were gamma irradiated (40 Gy). The two
vitrification media that were used, VS1 and VS2, were both
made from the same base of holding medium (HM), which
included D-MEM containing HEPES buffer supplemented
with 20% SR (Gibco). VS1 contains 10% dimethylsulf-
oxide (DMSO) and 10% ethylene glycol, and VS2 contains
20% of both DMSO and ethylene glycol (Sigma-Aldrich)
as well as 0.5 mol/l sucrose. Cell aggregates were incubated
in VS1 for 1 min, followed by 25 s of incubation in VS2. The
cell clumps were then washed in droplets of VS2 and then
placedwithinadropletof1–2μlVS2fromwherethecolonies
where loaded by capillary force into the narrow end of the
straw. The straw was then immediately submerged into liquid
nitrogen and then stored for a long term.
The thawing of vitrified straws was also performed as
described by Reubinoff and coworkers (2001). Directly
from liquid nitrogen, the straw was held in room temper-
ature for 3 s, and the narrow end of the straw was
submerged into SR-medium supplemented with 0.2 M
sucrose. When the medium within the straw was liquefied
and medium started to fill up the straw, the wide opening of
the straw was sealed. The straw was emptied into one well
of a four-well plate containing SR-medium supplemented
with 0.2 M sucrose and incubated for 1 min in 37°C. The
cell aggregates were moved to the next well containing SR-
medium supplemented with 0.1 M sucrose and incubated
for further 5 min in 37°C. The cell aggregates were then
moved to the third well containing SR-medium and
incubated for 5 min in 37°C. This step was repeated twice.
The cells were then plated in a fresh feeder plate.
Slow freezing. When hESCs need to be frozen in higher
scale, the slow freezing method is widely used (Reubinoff
et al. 2001). Undifferentiated hESC colonies (∼25) were cut
out from feeder layer using a surgical scalpel. Colonies
were added into cryovials, and the freezing medium
containing hESC culture medium without bFGF supple-
mented with 10% DMSO (Sigma-Aldrich) were added. The
vial were placed in a Nalgene Cryo 1°C Freezing Container
“Mr. Frosty” (Nalgene Nunc International, Rochester, NY)
containing isopropanol and immediately put into –70°C.
The next day, cryo vials were removed from –70°C and
placed into a liquid nitrogen tank.
Freezing with Rho-kinase inhibitor (Y-27632). In early
2009, there was a method describing cryopreservation of
dissociated hESCs in the presence of a ROCK inhibitor
(Merck Chemicals, Ltd.; Martin-Ibanez et al. 2008). Briefly,
cells that had been grown as single cells in present of
ROCK inhibitor were harvested by adding ROCK inhibitor
(10 μM) 1 h before detaching the cells from feeder layer
with TrypLE
TM express (Gibco). The dissociated cells were
transferred to freezing medium without bFGF, supple-
mented with 10% DMSO. Between 30,000 and 100,000
hESCs were loaded into a cryo vial and frozen at −70°C
using freezing container as mentioned earlier and then
stored in liquid nitrogen.
The thawing procedure of hESCs frozen in the presence
of ROCK is the same as in slow freezing with some
modifications. When seeding out hESCs onto fresh feeder
cells, the culture medium should contain ROCK inhibitor
(10 μM). When the medium were changed for the first time
after thawing, there were no longer necessary to add ROCK
inhibitor to the culture medium.
Karyotyping. Karyotyping of new cell lines were carried
out using standard G-banding techniques. Samples of
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Gibco) for 5 h. The colcemid-treated cells were removed
into a centrifugation tube and centrifuged at 1,300 rpm, for
7 min. In the meantime, cell cultures were treated with
trypsin for 5 min. Supernatant were removed after
centrifugation, and the trypsin-treated cells were added in
the tube and resuspended. Prewarmed 0.0375 M KCl
hypotonic solution were added in the tube and then
incubated for 10 min. Following centrifugation, the cells
were resuspended in fixative of methanol and acetic acid
(3:1). Metaphase spreads were prepared on glass micro-
scope slides and G-banded by brief exposure to trypsin and
stained with 4:1 Gurr´s/Leishmann´s stain (Sigma-Aldrich).
A minimum of 10 metaphases was analyzed.
Teratomas. The pluripotency of the new line together with
earlier control lines were tested in vivo as previously
described (Inzunza et al. 2005). In brief, exponentially
growing hESC lines were harvested from the culture plate
using mechanical splitting. Five colonies (10
3 to 10
4
hESCs) were washed twice in phosphate-buffered saline
(PBS) and put in a 1.5-mL collection tube and 80-μL SR-
containing culture medium, subsequently implanted be-
neath the testicular capsule of a young (7-wk-old) severe
combined immunodeficiency/beige male mouse (C.B.-17/
GbmsTac-scid-bgDF N7, M&B, Ry, Denmark). Teratoma
growthwasdeterminedbypalpationeveryweek,andthemice
were killed (cervical dislocation) 8 wk after implantation. The
teratoma was fixed, and sections were stained with hematox-
Table 1. The table includes all hESC lines derived at Karolinska Institutet between 2002 and 2009
hESC Line Day of Derivation Isolation of the ICM Medium Supplement Feeder Layer Karyotype Teratoma Formation
HS181 6 Immunosurgery 20% FCS hff 46,XX Yes
HS207 7 Immunosurgery 20% FCS hff 46,XY Yes
HS235 6 Immunosurgery 20% FCS hff 46,XX Yes
HS237 6 Immunosurgery 20% FCS hff 46,XX Yes
HS293 6 Immunosurgery 20% SR hff 46,XY Yes
HS306 5 Immunosurgery 20% SR hff 46,XX Yes
HS346 7 Immunosurgery 20% SR hff 46,XX Yes
HS351 6 Immunosurgery 20% SR hff 46,XX No
HS360 6 Immunosurgery 20% SR hff 46,XY Yes
HS361 7 Immunosurgery 20% SR hff 46,XY Yes
HS362 6 Immunosurgery 20% SR hff 46,XY Yes
HS363 6 Immunosurgery 20% SR hff 46,XY Yes
HS364 6 Immunosurgery 20% SR hff 46,XY Yes
HS366 6 Immunosurgery 20% SR hff 46,XX Yes
HS368 7 Immunosurgery 20% SR hff 46,XY Yes
HS380 6 Immunosurgery 20% SR hff 46,XY Yes
HS382 6 Immunosurgery 20% SR hff 46,XY Yes
HS400 6 Immunosurgery 20% SR hff 46,XX Yes
HS401 6 Immunosurgery 20% SR hff 46,XY Yes
HS402 6 Immunosurgery 20% SR hff – Yes
HS415 6 Mechanical 20% SR hff 46,XX Yes
HS420 6 Mechanical 20% SR hff 46,XY Yes
HS422 6 Mechanical 20% SR hff 46,XY Yes
HS426 8 Mechanical 20% SR hff 46,XY Yes
HS429 6 Mechanical 20% SR hff 46,XX Yes
HS475 7 Mechanical 20% SR hff – Yes
HS480 6 Mechanical 20% SR hff – Yes
HS481 6 Mechanical 20% SR hff ––
HS491 6 Mechanical 20% SR hff ––
HS539 5 Mechanical 20% SR hff ––
The first 20 hESC lines were derived by immunosurgery and the latest 10 by mechanical isolation of the inner cell mass. In the four first
derivations, the medium was supplemented with fetal calf serum (FCS); this was later replaced by adding serum replacement (SR) to the media.
All lines have not yet been karyotyped or tested for in vivo differentiation capacity
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embryonic germ cell layers was shown, as analyzed from the
stained sections (Inzunza et al. 2005).
All animal experiments were performed at the infection-
free animal facility of Karolinska University Hospital in
accordance with ethical committee approval.
Testing pluripotency in vitro. By culturing aggregates of
hESCs in suspension without bFGF for 3 wk, embryoid
bodies (EBs) were formed. The presence of tissue originat-
ing from the three embryonic germ layers was demonstrat-
ed using RT-PCR and immunohistochemistry for marker
genes of the three embryonic germ layers.
Immunostaining. Immunocytochemical characterization of
new hESC lines was carried out using primary antibodies
specific for Oct-4 (Chemicon), Nanog, TRA-1–60, TRA-1–
81, SSEA-1, and SSEA-4 (all from Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA), as negative control human
foreskin fibroblasts were used. Immunostaining was per-
formed by fixating cells with 4% paraformaldehyde in PBS
for 20 min at room temperature and washed with PBS three
times followed by blocking with 5% FBS for 30 min.
Permeabilization was carried out using 5% blocking buffer
consisting of 0.02% Triton X-100 (Sigma-Aldrich) in PBS.
Primary antibodies were added to blocking buffer over
night at 4°C. To remove any unbound antibodies, the
samples were washed three times with PBS. The secondary
antibody, fluorescein isothiocyanate (FITC)-conjugated
goat antimouse immunoglobulin G (IgG), Cy3-conjugated
goat antirabbit IgG, or FITC-conjugated bovine antigoat
IgG (all from Chemicon) were diluted 1:200 in 5%
blocking buffer and added to cells for 60 min at room
temperature in dark. After three washes with PBS, the cell
nuclei were counterstained with Hoechst B2261 (Sigma-
Aldrich) for 10 min.
In addition to negative control cells, we used primary
antibodies as a second negative control. Stained cells were
analyzed using an Olympus IX71 inverted microscope
(Olympus Sverige AB, Solna, Sweden), and images were
acquired with Olympus DP71 camera and the Soft Imagine
Cell F version 2.6 Software (Olympus Sverige AB).
Staining of EBs was performed in a similar way after
fixation with 4% paraformaldehyde for 1 h. After fixation
of the EBs, they were stained for markers specific for the
three germ layers; bone morphogenetic protein-4 (BMP-4)
for mesoderm (Novocasta Laboratories Ltd, Newcastle
upon Tyne, UK), nestin (Chemicon) for ectoderm, and
alpha-fetoprotein (AFP; Sigma-Aldrich) for endoderm.
Primary antibodies were added in 5% blocking buffer over
night at 4°C and later washed three times with PBS to
remove any unbound antibodies. FITC-conjugated goat
antimouse IgG, Cy3-conjugated goat antirabbit IgG, or
FITC-conjugated bovine antigoat IgG (all from Chemicon)
wereusedassecondary antibodiesand werediluted(1:200) in
5% blocking buffer and applied to cells for 60 min at room
temperature in dark. After two washes with PBS, the EBs
were counterstained withHoechst 33 342 (2 μg/ml, Sigma) or
PI (1 μg/ml, Sigma-Aldrich) for 10 min for nuclear staining.
RT-PCR analysis. RT-PCR was performed for BMP-4,
nestin, and AFP. From the EBs, total RNA was extracted
using Qiagen RNeasy Mini Kit (Qiagen, Germantown, Md)
protocol as previously described (Strom et al. 2007).
Results
The derived lines are presented in Table 1. Two lines were
derived from Day 5 embryos, 22 from Day 6, five from
Day 7, and one from Day 8 blastocysts. The derivation
process is illustrated in Fig. 1 in which the derivation of the
line HS475 is shown. The lines HS181–HS429 have been
describedearlier,butthelinesHS475,HS480,HS481,HS491,
and HS539 are presented for the first time in this article.
All the lines have been banked. Most of the lines have
been fully characterized, but the line HS402 was frozen
before karyotyping, and teratoma formation due to lack of
Figure 1. Derivation of the hESC line HS475. (A) Hatched blastocyst
at Day 7 after fertilization, just before mechanical isolation of the
ICM. (B) The ICM after derivation on human feeder layer. (C)
Outgrowth of the ICM, 5 d after derivation. (D) HS475 at passage
level 1. (E) HS475 at passage level 5. Magnification: (A) 200x (B, C)
400x (D, E) 40x original magnification.
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of hESC colonies. (a) HS181 on
Matrigel, 40 x original magnifi-
cation (b) HS401 on Matrigel,
400 x (c) HS366 on hff, 40 x.
(d) HS420 on hff, 400 x.
Figure 3. Characterization of hESC lines by immunocytochemistry.
(a) HS401 p37 Positive staining for nuclear marker Nanog (b) 366
p35 staining for nuclear marker Oct 3/4 (c) 362 p36 staining for
TRA1–81 (d) 362 p36 staining for TRA-1–60. Magnification (a, c)
100× (b, d) 200× original magnification.
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HS475, HS480, HS481, HS491, and HS539 are in the
process of these analyses. All these lines expressed all the
studied pluripotency markers and markers of the three germ
layers after in vitro differentiation to embryoid bodies.
They are now in culture for karyotyping and teratoma
formation. All the other lines expressed the pluripotency
markers were pluripotent in both teratoma assay, and after
in vitro differentiation to embryoid bodies. All the lines had
a normal karyotype when for the first time analyzed. One of
our lines, HS237, had a diisocentric X-chromosome at
passage level as revealed by comparative genomic hybrid-
ization (Inzunza et al. 2004). In our hands, the other lines
have remained karyotypically normal, but other teams have
obtained abnormalities in the line HS181 (Inzunza et al.
2004) which has been the most widely distributed of our
lines. The lines have been widely distributed into more than
100 laboratories. The lines HS181, HS207, HS237, HS293,
HS306, HS346, HS415, HS420, HS422, HS426, and
HS429 have been accepted by the European commission
for use in the integrated project ESTOOLS. The most recent
line, HS539, was obtained fresh from the preimplantation
genetic diagnosis program of the IVF unit. The exclusion of
Huntington’s disease form the donated embryo was carried
out indirectly using single nucleotide polymorphism assay
because the parent did not want to know if she is a carrier
of Huntington’s disease. From the embryo donated for
research, the exclusion could not be done.
Some of our oldest lines, among them HS181, have been
kept timewise in culture for more than 200 passages, and
the most resent one, HS539, has only been growing for
seven passages.
Typical morphology of hESC colonies on hff and on
Matrigel is shown in Fig. 2.F i g u r e2a, b illustrates HS181
and HS401 in feeder-free culture on Matrigel and in mTeSR1
medium, and Fig. 2c, d shows HS366 and HS420 on hff.
Typical characterization by immunostaining from the lines
HS362, HS366, and HS401 shows expression of Oct3/4,
Nanog, TRA-1–60, and TRA-1–81 (Fig. 3).
Discussion
We have successfully derived a large number of lines with
the aim of optimizing the quality of the hESC lines for
various research projects and in preparation for clinical grade
xeno-free good manufacturing practice (GMP)—quality
hESC line derivation. Our present efforts are focused on
feeder-free derivation, which would greatly simplify the
GMP processes (Unger et al. 2008), but there still remain
problems to be solved before safe clinical applications of
hESC-differentiated cells are feasible. Tumorigenicity is the
most important one (Blum and Benvenisty 2008).
It is important now to continue the work for derivation
and culture of complete xeno-free hESC lines in fully
defined conditions, not only for clinical aspects but also in
order to obtain reliable results for basic research using the
incomparable tool that the hESC lines are for us in a wide
range of areas.
The great promise of the iPS cells does not make research
on hESC redundant. Differentiation of iPS cells benefits
from all protocols developed using hESC (Park et al. 2008).
Tumorigenicity of iPS cell is still an open question.
Our present lines are not of clinical grade, but if culturing
of old lines in GMP laboratories, to verify their safety, will
be accepted by authorities, our lines offer a good selection of
genotypes of lines which have been derived in cleaner
conditions than most of the other reported lines. We can
today offer a good number of hESC lines for the embryonic
stem cell research community. More than 100 laboratories
are using them. The lines are registered in the EU hESC
registry (http://www.hescreg.eu/).
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